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Title: Incidence of submacular haemorrhage (SMH) in Scotland: a Scottish Ophthalmic Surveillance 
Unit Study (SOSU) study 
 
Authors: A Al-Hity, David H Steel, David Yorston, David Gilmour, Zachariah Koshy, David Young, 
Jost Hillenkamp, Gerard McGowan 
 
Purpose: Submacular haemorrhage is a cause of severe visual loss in neovascular age-related 
macular degeneration (nAMD). The incidence is uncertain and furthermore there is no widely-used 
classification system nor agreed best practice. The aim of this national surveillance study was to 
identify the incidence, presenting features and clinical course of new fovea-involving submacular 
haemorrhage associated with nAMD.  
 
Method: A questionnaire was sent monthly to every ophthalmic specialist in Scotland over a 12-
month period asking them to report all newly presenting patients with acute fovea-involving SMH 
secondary to nAMD of at least 2 disc diameters (DD) in greatest linear diameter. A follow up 
questionnaire was sent 6 months after initial presentation. Cases related to other causes were 
excluded. 
 
Results: Twenty-nine cases were reported giving an incidence of 5.4 per million per annum but with a 
wide range across regions of 2-15. . The mean age was 83 years (range 66-96) and females 
accounted for 17/29 (59%). 15/29 (52%) had a past history of AMD, of which 7 was nAMD. 19/29 
(66%) presented within 7 days of onset and the majority had SMH of less than 11 disc diameters 
(20/29,69%). Treatment options comprised: observation (n=6, 21%), anti-VEGF alone (n=6, 21%) or 
vitrectomy with co-application of tPA, anti-VEGF and gas (n=17, 58%). The vitrectomy group 
experienced the greatest change in vision from logMAR 1.89 to 1.50. (p=) Four out of 20 (20%) cases 
with 6 months follow up suffered a re-bleed at a mean time of 96 days. The incidence of submacular 
haemorrhage was calculated at 5.4 per million per year. 
 
Conclusion: The incidence, clinical features and course of a consecutive national cohort of patients 
with SMH secondary to nAMD are presented.  
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INTRODUCTION 
The prognosis for neovascular age-related macular degeneration (nAMD) has been transformed by 
the use of intravitreal anti-vascular endothelial growth factor (anti-VEGF) drugs. Some patients, 
however, still have poor outcomes. One cause of severe visual loss in nAMD is submacular 
haemorrhage (SMH). This is relatively uncommon, but has a very poor prognosis untreated. {{503 
Scupola,A. 1999;}} (25) 
 
The optimum treatment of wet AMD complicated by significant SMH is uncertain. To date, several 
studies have suggested that treatment with anti-VEGFs alone may be superior to observation whilst 
others have suggested that displacement of blood with gas and sub-retinal or intravitreal tPA and anti-
VEGF may be more optimal., Identifying the incidence of this complication and its optimal treatment 
has obvious implications for public health and cost effectiveness. (1-7) 
 
The best evidence to determine if these more invasive procedures really represent an advance over 
management with intravitreal anti-VEGF alone would be a randomised clinical trial (RCT). To assist 
the design of such a trial, data on the incidence, natural history and outcome of patients presenting 
with SMH in the era of anti-VEGF treatment is needed. We therefore designed a national prospective 
observational study in Scotland, UK. Specifically, we aimed to assess the incidence of SMH occurring 
secondary to nAMD, the clinical features at presentation, the treatment modalities currently being 
used and finally prognostic factors which could help in future decision making.  
 
METHODS 
This was a population-based, prospective observational study with active surveillance of cases 
through the Scottish Ophthalmological Surveillance Unit (SOSU) monthly reporting card scheme. 
SOSU has the same methodology as its sister organisation, the British Ophthalmological Surveillance 
Unit (BOSU) where several studies have been conducted previously. (8-12) Both were established to 
assist in the investigation of the incidence and clinical features of rare eye conditions of scientific and 
public health importance. The BOSU steering committee review all protocols of individual studies in 
order that certain basic criteria are met and to provide advice on the design of their questionnaires 
and studies. (13) 
 
The SOSU surveillance scheme involves all consultant or associate specialist ophthalmologists with 
clinical autonomy in Scotland who form the reporting base. Ophthalmologists were asked to notify the 
study investigators, through the SOSU of all newly diagnosed cases of fovea-involving SMH of size 
greater than 2-disc diameter (DD). Case notifications were requested over the 12-month study period 
September 2013 to September 2014. All SMH not related to AMD were excluded. 
 
Following case notification to the SOSU, every consultant ophthalmologist in Scotland was sent a 
detailed questionnaire by the study investigators requesting data on: visual acuity, lens status, fellow 
eye status, duration of symptoms (recorded as 1-7, 8-14, >14 days), previous treatment for SMH, size 
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of haemorrhage (recorded in groups 1-6, 7-11, 12-16 and >16 disc diameters (DD)), past history of 
nAMD, ocular co-morbidities, time to treatment and initial management. Outcome data were obtained 
from follow-up questionnaires sent to the reporting ophthalmologists 6 months after diagnosis. Follow-
up data collected comprised: subsequent treatment, follow-up visual acuity, complications (re-bleed) 
and sight impairment registration details eligibility (partial/ severe). Ophthalmologists who did not 
return questionnaires were sent repeat request letters at 2 and 3 months after the initial request had 
been sent. The response rate was calculated as the number of questionnaires received over the total 
reporting cards received. (13)  
 
Statistical analysis was performed with presentation of mean or median and range as appropriate. 
Visual acuity was converted to logMAR for analysis and paired t tests used to compare vision pre and 
post intervention. A p value of less than 0.05 was considered significant and a general linear model 
for significance. 
 
Incidence rate 
Scotland has been recognised in previous studies as a well-defined region with stable population 
demographics. (10,14) The proportion of the Scottish population of retirement age (65 years) has 
been shown to be relatively stable and representative of the whole UK population (18.0% vs 17.7%, 
respectively) and as such the Scottish population can be used as a focus population in a similar 
manner to previous studies. (10,15) . The male to female ratio is 49%:51%. The incidence rate was 
calculated as the number of reported cases as a proportion of the total population over the 1-year 
study period. The number of cases were also tracked to the source NHS trust in order to calculate the 
incidence per specific region of Scotland.
 
RESULTS  
Over the 12-month period between September 2013 and September 2014, a total of 29 yellow cards 
with reported cases (29 eyes) were returned and 29 initial questionnaires received giving a response 
rate of 100%. Six month follow up data was received on 20 of the 29 cases. The total Scottish 
population in 2013 was 5,327,700 giving an overall incidence of 5.4 per million per annum. The 
incidence varied by region from 15 per million in the Greater Glasgow and Clyde region (17 cases 
with a population of 1,137,000) to 2 per million in the Grampian region (1 case with a population of 
526,000). 
 
TRUST OF REPORTED CASES POPULATION CASES INCIDENCE 
NHS GREATER GLASGOW AND CLYDE 1,137,000 17 15.0 
NHS AYRSHIRE AND ARRAN 400,000 3 7.5 
NHS TAYSIDE 415,000 2 4.8 
NHS LOTHIAN 800,000 3 3.8 
NHS FORTH VALLEY 281,000 1 3.6 
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NHS HIGHLAND 320,000 1 3.1 
NHS FIFE 359,000 1 2.8 
NHS GRAMPIAN 526,000 1 1.9 
 
Table 1 Reported cases and incidence per regional Scottish NHS trusts 
 
Baseline data is presented in Table 1.  The mean age was 83 years with 17 (59%) females. Fifteen 
(52%) had a past history of AMD of which 7 was nAMD. A total of 19/29 (66%) presented within 1-7 
days of onset of symptoms. 7/29 (24%) presented greater than 2 weeks after onset of symptoms. 
Eleven (38%) had a SMH of size 7-11 DD while a further 9/29 (31%) were of size 2-6 DD.  
 
 
Table 2 Clinical features at baseline 
 
Age, years(mean, range) 83, 66-96 
Sex n (%)  
Female 
Male 
 
59% 
Visual acuity, logMAR (mean, range) 1.85, 0.8-2.3 
Fellow eye visual acuity 0.94, 0.2-2.3 
Duration of symptoms, Days n(%) 
1-7  
8-13 
>14 
 
19 (66%) 
3 (10%) 
7 (24%) 
Size of SMH, DD n(%) 
2-6 
7-11 
12-16 
>16 
 
9 (31%) 
11 (38%) 
3 (10%) 
6 (21%) 
Known ocular co-morbidity of affected eye n(%) 
None 
Dry AMD 
nAMD 
OHT 
 
13 (45%) 
8 (28%) 
7 (24%) 
1 (3%) 
Lens status n(%)  
Phakic 
Pseudophakic 
 
69% 
Initial treatment n (%) 
Observation 
IVT aflibercept 
IVT ranibizumab 
 
6 (21%) 
1 (3%) 
5 (17%) 
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PPV/ SRET tPA/ SRET ranibizumab/ GAS 17 (58%) 
Time to treatment (days) Mean (range) 
Anti-VEGF 
Vitrectomy  
Overall  
 
38 (6-55) 
3 (0-6) 
10 (0-55) 
  
[VA - Visual acuity, SMH ± submacular haemorrhage, DD ± disc diameter, AMD 0 age related macular degeneration, nAMD ± 
neovascular age related macular degeneration, PPV - Pars Plana Vitrectomy, IVT - Intravitreal, SRET - sub retinal). N=29 for 
all values. 
 
 
Treatment modalities 
There were 3 management strategies observed: observation, anti-VEGF agents  alone (either 
ranibizumab or aflibercept) and  vitrectomy and co-application of intra-vitreal or subretinal  tPA/anti-
VEGF (see Table 1). No cases with expansile gas and intravitreal tPA/ Anti-VEGF were reported 
either as initial treatment or subsequently.   
 
Table 3 Follow-up data. 
 
Subsequent treatment n (%) 
None 
IVT ranibizumab 
 
7 (35%) 
13 (65%) 
Final visual acuity (mean, range) 1.61, 0-3 
Final visual acuity fellow eye (mean, range) 0.91, 0-2.3 
Re-bleed n (%) 4 (20%) 
Sight impairment registration n (%) 
None 
Sight impairment  
Severe sight impairment  
Not known 
 
10 (50%) 
5 (25%) 
3 (15) 
2 (10%) 
 
VA - visual acuity, IVT ± intravitreal). N=20 for all values. 
 
 
Visual acuity 
Overall the mean visual acuity non-significantly improved from 1.85 at baseline to 1.61 (p=0.072) with 
differences, again non-significant between the groups, but with the greatest effect seen in the 
vitrectomy group.  Eligibility for treatment in the UK NHS is dependent on being better than the UK 
NICE visual acuity cut off of 25 ETDRS letters (1.2 logMAR) or better. Of the 29 cases, 6 (20.7%) met 
these criteria. This percentage rose to 35.0% (7/20) at follow-up. Subsequent treatment was given in 
13/20 (65.0%) of cases, all receiving intravitreal ranibizumab. The mean number of injections given 
was 2 (range 1-6). 
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 n 
Baseline  VA Final  VA 
Change in VA  
p 
value VA SD Range VA SD Range 
Observation 6 1.83 0.55 1.04 - 2.30 1.81 0.82 1.14 - 3.00 -0.02 0.48 
Anti-VEGF alone 6 1.72 0.57 1.00 - 2.30 1.77 0.68 1.00 - 2.30 0.05 0.45 
Vitrectomy 17 1.89 0.49 0.8 - 2.30 1.5 0.79 0 - 2.30 -0.39 0.35 
 
Table 4 Changes in visual acuity across the three management groups. (VA - visual acuity, SD - 
standard deviation, VEGF - Vascular endothelial growth factor) 
 
 
 
  
Figure 1 Initial and final logMAR visual acuity across reported management groups (Observation ± green, Anti-VEGF 
alone ± red, vitrectomy ± blue)7KHOLQHUHSUHVHQWV3HDUVRQ¶VOLQHRIFRUUHODWLRQRIWKHZKROHFRKRUW 
 
 
Duration of symptoms 
Those presenting within the median of 1- 7 days of onset of symptoms showed a mean improvement 
in visual acuity from 1.76 to 1.37 (-0.39). Conversely, those presenting greater 7 days had a decline in 
visual acuity at follow-up from 1.78 to 1.87 (0.09). Overall, the duration of symptoms was not a 
significant predictor of final visual acuity (p=0.381)  
 
Size of haemorrhage 
The median size of SMH was 7-11 DD. There was no significant differences in baseline and follow up 
between any of the groups but the greatest improvement was seen in the smallest SMH size group of 
 7 
2-6DD (p=0.251) In contrast, a decline in mean visual acuity was seen in haemorrhages of greater 
than 16 DD (see Table 4)  
 
Size of SMH 
(DD) 
n Baseline VA Final  VA Change in 
VA  
p 
value VA SD Range VA SD Range 
2 - 6 9 1.51 0.48 1.04 - 2.00 1.21 0.26 1.14 - 1.5 -0.3 0.2 
7 - 11 11 1.8 0.6 0.8 - 2.30 1.73 0.89 0.50 - 3.00 -0.07 0.42 
12 - 16 3 2.2 0.17 2.00 - 2.30 2.15 0.21 2.00 - 2.30 -0.05 0.39 
> 16 6 1.74 0.6 1.00 - 2.30 1.78 0.56 0.8 - 2.30 0.04 0.33 
 
Table 5 Changes in visual acuity with different size of Submacular haemorrhage. VA ± visual acuity, 
SD ± standard deviation, DD ± disc diametres 
 
 
Complications 
4/20 (20%) suffered re-bleeds with a mean time of 96 days (range 52-170) from the date of treatment. 
One case was in the observation group while the other 3 were in the surgical group. The mean visual 
acuity in this group improved from 1.95 to 1.77 despite the rebleed. Three out the 4 (75%) were 
treated with subsequent anti-VEGF. At 6-month follow-up, 8/20 (40%) were eligible for sight 
impairment registration and 3 (15%) registered as severely sight impaired.  
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DISCUSSION 
In this study, we presented data from a national surveillance study into all cases of acute submacular 
haemorrhage over a 12-month period in Scotland. Through this prospective study, we have identified 
the incidence rate of fovea-involving submacular haemorrhage of 5.4 per million per year. It was 
noted on postcode data that the incidence varied greatly by region ranging from 15 per million to 2 per 
million. There are a number of reasons for these variations. The first may be a degree of under-
reporting which is evident in any surveillance scheme, although the response rate from participating 
ophthalmologists in the BOSU scheme has been consistently more than 70%. (13) Secondly, patients 
may fail to present due to access to healthcare. For example, NHS Highland covers an estimated 
area of 12,500 square miles and serves a population of 320,000. In contrast to this, NHS Greater 
Glasgow and clyde has a population of 1,137,000 and 17 reported cases (incident rate of 15 per 
million per year). With an area of 452 square miles, Its important to know that its population density is 
much higher than NHS Highland at 2,515 people per square mile (compared to just 26 people per 
square mile). This might have contributed to the variations in reporting rates. One can also suppose 
that these differences across regions are genuine, however this was not seen in a pilot study which 
showed comparable incidence rates between Sunderland and Glasgow (24 per million per year) 
although these are very comparable areas in terms of population density, healthcare provision and 
deprivation indices. (7)  A smaller size haemorrhage (<7 DD) was associated with a better visual 
prognosis. Conversely, massive submacular haemorrhages (>16 DD) were associated with a poorer 
visual prognosis as found by previous studies. (7) 
 
In our study, those that were observed showed a slight decline in visual acuity whilst those who were 
treated surgically showed some, albeit non-significant improvement in visual acuity. Surgical 
intervention was exclusively with pars plana vitrectomy and co-application of tPA/anti-VEGF with gas 
exchange. This intervention has been associated with complete displacement of the submacular 
haemorrhage and improvement in post-operative visual acuity. (5) Furthermore, the surgical 
intervention in this case led to an increase in the percentage of patients (18% to 42%) who were 
eligible for intravitreal anti-VEGF as based on the UK vision criteria which may justify its use in cases 
where no alternative therapy is indicated. Patients treated with anti-VEGF agents alone resulted in 
maintained and in certain cases, improved visual outcomes compared to the natural history of the 
submacular haemorrhage which concurs with previous reports. (1-2,17-19, 24-25) It is interesting 
however to note that those who were treated with anti-VEGF alone waited a mean number of 38 days 
while those who were treated surgically waited a mean number of 3 days. Whilst it is known that 
prompt surgical treatment improves outcomes, the relationship between treatment time and outcome 
with anti-VEGF alone is unclear but the anti-VEGF trials showed duration of symptoms prior to 
treatment was related to outcome so it can be concluded that prompt treatment, even with anti-VEGF 
alone can help prevent severe visual loss. (1-2,17-19) The pressures of service delivery, especially in 
the National Health service, mean that it is often days or weeks until patients are seen, have the 
appropriate diagnostic investigations, a management plan is arranged and executed. Strategies to 
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highlight time sensitive conditions such as SMH must be in place if severe visual loss is to be 
prevented. 
  
 
It is interesting to note that there were no reported cases of the use of pneumatic displacement with 
intravitreal tPA although this has been widely reported as an effective strategy combined with anti 
VEGFs previously.(17-21). Having said this, the relative efficacy of expansile gas and intravitreal TPA 
compared to vitrectomy with subretinal TPA and air or gas is uncertain. A recent RCT showed no 
difference in results between the two modalities but previous studies have shown a higher efficacy of 
subretinal TPA over intravitreal TPA in terms of displacement of blood eccentrically to fovea. (22-23) 
A study of vitrectomy combined with subretinal TPA and air reported 3 cases that were successfully 
displaced that had previously failed to displace with expansile gas and intravitreal TPA and the 
vitrectomy technique may offer advantages in patients unable to posture. (4)  It appears that in 
Scotland displacement with the expansile is not popular which may be due to a variety of possible 
reasons including personal surgical preference, patient choice and the lack of ability, or perceived 
risks of posturing in the age group affected. (21) 
 
The evidence base for the treatment of SMH associated with AMD largely comprises case-series 
which tend to focus on surgeon-selected cases and a variety of criteria to guide individual treatment 
choices. Therapeutic decision-making is difficult due to a lack of standardisation in both the 
classification of SMH and outcome reporting. (16) The strength of this study is that we report on the 
presentation and management of all cases over a one-year period with 6-month follow data to give a 
true picture of the cases seen in clinical practice and real world outcomes from a range of 
management options and which we hope will help guide the design of a future RCT.  There are 
however several limitations to the study, including the lack of access to fundal imaging to ascertain 
the precise features of the haemorrhages and absence of protocol refracted visual acuities. Follow up 
was also limited to 6 months and incomplete.   
  
In conclusion, this prospective national surveillance study has identified an incidence for submacular 
haemorrhage of 5.4 per million per year but with a wide range of 2-15. In addition, we highlight the 
benefit of prompt surgical intervention in the quest to improve vision. It is hoped that this surveillance 
study will inform future randomised control studies.  In particular, further studies are indicated to 
clearly define the role of surgical intervention as compared to anti VEGF treatment alone in the 
treatment of fovea-involving submacular haemorrhage. 
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